IP Library › Granted Patent US 10,421,754
Granted Patent B2
US 10,421,754 · App. 15/503,323 · Granted Sep 24, 2019

Quinazoline derivative

Inventors: Ying Shi (Shijiazhuang, CN); Qingzhi Gao (Shijiazhuang, CN); Xiaozhuo Chen (Shijiazhuang, CN); Yi Mi (Shijiazhuang, CN); Yaran Zhang (Shijiazhuang, CN); Hanyu Yang (Shijiazhuang, CN); Yujie Chen (Shijiazhuang, CN); Chunlei Liu (Shijiazhuang, CN); Guorui Mi (Shijiazhuang, CN); Yuxiu Ma (Shijiazhuang, CN); Dongmin Shen (Shijiazhuang, CN); Yang Guo (Shijiazhuang, CN); Linjing Fan (Shijiazhuang, CN)
Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
C07D417/12A61K31/517A61P35/00C07D239/94C07D401/12C07D403/12C07D405/12C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,421,754
App. No.
15/503,323
Granted
Sep 24, 2019
Kind
B2
Abstract

Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.

Claims (21)

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof,

wherein

R 1 is —O(CH 2 ) n R 3 ,

wherein

n is 3, 4 or 5, and

R 3 is —NR e R f ,

wherein R e and R f are each independently selected from a group consisting of C 1-6 alkyl, or R e and R f are taken together to form —(CH 2 ) 4 —; and

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof,

wherein R e and R f are C 1 alkyl.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from:

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:

5. A pharmaceutical composition, comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition, comprising the compound of claim 2 or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition, comprising the compound of claim 3 or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition, comprising the compound of claim 4 or a pharmaceutically acceptable salt thereof.

9. A method for preparing the compound of claim 1 or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (III) or its salt with a compound of formula (IV) or its salt in a solvent and optionally in the presence of one or more of a catalyst, a base and a surfactant, to obtain the compound of formula (I),

wherein:

R 1 , R 2 , R 3 and n are as defined in claim 1 ,

L represents halogen, hydroxyl, mesyloxy or hydrogen; and

p=0 or 1, with the proviso that when p=1, L is hydrogen.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: SHI, YING; GAO, QINGZHI; CHEN, XIAOZHUO; MI, YI; ZHANG, YARAN; YANG, HANYU; CHEN, YUJIE; LIU, CHUNLEI; MI, GUORUI; MA, YUXIU; SHEN, DONGMIN; GUO, YANG; FAN, LINJING
To: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
Reel/Frame 042252/0832 →
Priority Claims (1)
CN 2014 1 0391653 · Aug 11, 2014 · national
Continuity (1)
Related Publication 20170226099A1 · Aug 10, 2017
Cited By (1)
US 12,637,434